Back to results
US 12,496,310 B2Granted
Compositions and methods for adoptive cell therapy
AssigneeMemorial Sloan Kettering Cancer Center
InventorsDavid A. Scheinberg, Thomas J. Gardner, Derek S. Tan, Jonghan Lee
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions and methods for adoptive cell therapy comprising engineered immune cells that express an antigen-targeted chimeric antigen receptor and a prodrug converting enzyme for the treatment of inflammation, inflammatory diseases, or pathogenic infections.
Claims7
An engineered immune cell comprising:
- (a) a prodrug converting enzyme and/or a nucleic acid encoding the prodrug converting enzyme, wherein the prodrug converting enzyme is Pseudomonas sp. Carboxypeptidase G2 (CPG2) or Enterobacter cloacae β-lactamase;
- and
- (b) a chimeric antigen receptor (CAR) comprising a first transmembrane domain, wherein the CAR is expressed on the surface of the engineered immune cell and binds to a target antigen, and/or a nucleic acid encoding the CAR, wherein the CAR targets the engineered immune cell to a site of pathogenic infection and wherein the target antigen is an antigen from a pathogen,
- wherein the prodrug converting enzyme is:
- (i) secreted from the engineered immune cell, or
- (ii) expressed on the surface of the immune cell and is
- (A) fused to a second transmembrane domain;
- or
- (B) attached to the surface of the cell by a GPI anchor, wherein the first transmembrane domain of the CAR is separate from the second transmembrane domain of the prodrug converting enzyme,
- wherein the antigen from the pathogen is a bacterial antigen, a parasitic antigen, a HSV-1 protein antigen, a HSV-2 protein antigen, or an HIV-1 protein antigen.
7 more elements
Dependencies are inferred from the claim text.